Anti-Cd19/22-Car Vector-Transduced T Cells
Recurrent Adult Diffuse Large Cell Lymphoma
Chinese PLA General HospitalCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Recurrent Adult Diffuse Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | BBB |
FILGRASTIM Ruijin Hospital | Phase 3 | BBB |
Busulphan Washington University School of Medicine | Phase 3 | BBB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 3 | BBB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
View all 48 →
Same molecule, other indications
Anti-Cd19/22-Car Vector-Transduced T Cells is also rated in:
B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)Dormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →